Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma
Interventions: PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Gemcitabine|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Naxitamab|BIOLOGICAL: Universal Donor Expanded TGF-beta-imprinted NK Cells
Sponsor: Margaret Gatti-Mays